-

10:34:36 AM

SVA Stock News

SVA - Sinovac Biotech, Ltd.

08/03/22 6:00 AM

Nasdaq : SVA

covid-19

SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that based on related clinical trials and studies of vaccination for local children and adolescents, the Health Bureau of the Government of the Hong Kong Special Administrative Region of the People’ s Republic of China has approved the Company’ s COVID-19 vaccine,...

RHEA-AI

neutral

07/19/22 1:30 AM

Nasdaq : SVA

clinical trial

SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that a phase III clinical trial for SINOVAC’ s inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile through a collaboration with the Pontificia Universidad Católica de Chile. In total, there will be 1,600 volunteers recruited, half of...

RHEA-AI

neutral

07/14/22 5:10 AM

Nasdaq : SVA

covid-19

SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that its COVID-19 vaccine has been approved by the Brazilian Health Regulatory Agency for emergency use in children from 3 to 5 years old on 13 July. Participants in this evaluation activity were the Brazilian Society of Pediatrics, the Brazilian Society of...

RHEA-AI

neutral

06/25/22 12:30 AM

Nasdaq : SVA

covid-19

SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that the South African Health Products Regulatory Authority granted conditional registration to SINOVAC CoronaVac ® in aged 18 and above adults, based on acceptable safety, quality, and efficacy data submitted. The CoronaVac ® was previously authorized for...

RHEA-AI

very positive

06/08/22 10:00 PM

Nasdaq : SVA

SINOVAC Polio Vaccine Prequalified by WHO

SINOVAC Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that it received the World Health Organization prequalification for its Poliomyelitis Vaccine on June 2, 2022. The vaccine will be available for United Nations agencies to purchase to support the global polio endgame strategy. SINOVAC's sIPV is applicable...

RHEA-AI

neutral

05/06/22 6:00 AM

Nasdaq : SVA

SINOVAC Updates the Status Under Holding Foreign Companies Accountable Act

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, is aware that the Company has been identified by the United States Securities and Exchange Commission under the Holding Foreign Companies Accountable Act of the United States on May 4, 2022. Sinovac Biotech Ltd. is a China- based biopharmaceutical company that focuses on the...

RHEA-AI

neutral

04/29/22 6:30 PM

Nasdaq : SVA

earnings

SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20- F with the U.S. Securities and Exchange Commission for the year ended December 31, 2021. Sales for the six months ended December 31, 2021 were $8.4 billion, compared to $442.9 million in the prior year period. Sales in 2021 were $19.4...

RHEA-AI

neutral

02/22/22 8:30 AM

Nasdaq : SVA

Sinovac Amends Shareholder Rights Plan

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. SINOVAC Biotech Ltd. is a China- based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human...

RHEA-AI

neutral

12/30/21 4:05 PM

Nasdaq : SVA

earnings

SINOVAC Reports Unaudited First Half of 2021 Financial Results

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2021. Sales for the six months ended June 30, 2021 were $11.0 billion, compared to $67.7 million in the prior year period. The Company posted $5.1 billion of net income attributable to common...

RHEA-AI

neutral

12/09/21 2:26 PM

Nasdaq : SVA

Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment

SINOVAC Biotech Ltd., a leading provider of biopharmaceutical products in China, today provided an update for shareholders with regard to the exchange of preferred share purchase rights for the Company’ s Common Shares and Series B Convertible Preferred Shares, originally announced via press release on February 22, 2019. On December 19, 2018, the High Court...

RHEA-AI

neutral

SVA Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.sinovacbio.com
CeoWeidong Yin
Security nameSinovac Biotech, Ltd.
Issue typecs
SectorManufacturing
Sic code2834
Employees1959
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressNo. 15 Zhi Tong Road,
Address2Zhongguancun Tech Park, Changping Distr.
StateBeijing
CityBeijing
Zip102200
CountryChina (Mainland)
Phone861082890088

About Sinovac Biotech, Ltd.

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza, 23-Valent Pneumococcal Polysaccharide ('PPV'), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella vaccine and mumps. Healive, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. The Company is developing a number of new products including COVID-19 vaccine, CoronaVac, a Sabin-strain inactivated polio vaccine and combined vaccines. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company is seeking market authorization of its products in over 30 countries outside of China.